Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,556.37
(
-0.37%
)
US TECH 100
23,360.00
(
-0.68%
)
Dow Jones
46,124.06
(
-0.18%
)
Brent Oil
95.84
(
-0.98%
)
Bitcoin
69,916.00
(
-1.39%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 183553

Tuesday, 04/07/2015 8:21:05 PM

Tuesday, April 07, 2015 8:21:05 PM

Post# of 257275
GILD submits NDA for “TAF-Truvada” FDC:

http://finance.yahoo.com/news/gilead-submits-drug-application-u-215600809.html

TAF-Truvada, which GILD refers to as “F/TAF,” differs from Truvada insofar as Viread has been replaced by TAF. The FDC comes in low (10mg) and high (25mg) doses of TAF.

The above PR states that the European MAA for TAF-Truvada will be submitted in 2Q15 (the current quarter).

GILD submitted an NDA and MAA for TAF-Stribild (which GILD refers to as “E/C/F/TAF”) in 4Q14 (#msg-107899029). The TAF-Stribild MAA was validated on 12/28/14, according to the above PR.

The commercial uptake of TAF is the biggest single risk for GILD investors, IMO (#msg-107185965, #msg-106583794, #msg-106586262).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today